Search results
Results From The WOW.Com Content Network
Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...
Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment ...
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26 th Annual Global Investment Conference, being held in New York.
(Reuters) -Cassava Sciences will form a committee to evaluatenew probes by U.S. regulators and investigate two senior employees, it said on Monday, days after a medical professor linked to the ...
Cassava shares surged from $7 in January 2021 to above $135 in July 2021 on investor hopes the company was on the verge of a breakthrough in treating Alzheimer's, a common form of dementia.
Cassava Sciences (NASDAQ:SAVA) is a clinical-stage biotechnology company that is taking on Alzheimer’s disease. In the past several months, short-sellers, law firms and other detractors have ...